Compare KXIN & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KXIN | CYCN |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 7.6M |
| IPO Year | N/A | N/A |
| Metric | KXIN | CYCN |
|---|---|---|
| Price | $7.62 | $1.71 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 323.9K | ★ 4.2M |
| Earning Date | 11-26-2019 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $95,000.00 | ★ $2,855,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1371.65 |
| 52 Week Low | $2.94 | $1.16 |
| 52 Week High | $55.50 | $6.25 |
| Indicator | KXIN | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 73.48 | 56.86 |
| Support Level | $4.87 | $1.16 |
| Resistance Level | $6.20 | $2.28 |
| Average True Range (ATR) | 0.80 | 0.13 |
| MACD | 0.20 | 0.05 |
| Stochastic Oscillator | 91.80 | 50.06 |
Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.